Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has worked faithfully but unsuccessfully to produce a single therapy, variously named Pro 140, leronlimab, and Vyrologix.

In development of this therapy, CytoDyn has cast its net wide and far both geographically and in terminology of prospective indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll actually be being used is an open question.

While CYDY  happens to be dawdling, promote opportunities for leronlimab as being a combination therapy in the therapy of multi-drug-resistant HIV happen to be closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale of the past few shares of mine. The first CytoDyn post of mine, “CytoDyn: What In order to Do When It’s Too Good to be able to Be True?”, set away what follows prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan presented such an extremely promotional image in the Uptick Newswire interview that I came away with a bad viewpoint of the business.

Irony of irony, the poor viewpoint of mine of the business enterprise has grown steadily, though the disappointment hasn’t been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > six bagger at the moment still disappoints? Therein sits the story; permit me to explain.

CytoDyn acquired its much storied therapy (which I shall relate to as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for your treatment and reduction of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti viral activity in HIV infected subjects. Today’s payment of $3.5 million transfers ownership of this know-how as well as linked intellectual property coming from Progenics to CytoDyn, as well as roughly 25 million mg of bulk drug substance…. milestone payments upon commencement of a phase III clinical trial ($1.5 huge number of) and the very first new drug application endorsement ($5 million), and even royalty payments of 5 % of net sales after commercialization.

Since that point in time, CytoDyn’s helping nous, Nader Pourhassan [NP] has turned this inauspicious acquisition into a springboard for CytoDyn to acquire a market cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with numerous indications and multiple therapies, it’s this individual therapies in addition to a “broad pipeline of indications” as it puts it. I call certain pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a potentially advantageous therapy of dozens of indications.

Its opening banner on its site (below) shows an active company with diverse interests albeit centered on leronlimab, several illness sorts, multiple publications and multiple delivering presentations.

Can all this be smoke and mirrors? That is a question I’ve been asking myself from the really beginning of the interest of mine in this particular organization. Judging by the multiples of a huge number of diverse comments on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I am much from alone in this particular question.

CytoDyn is a traditional battleground, or possibly some might say cult stock. Its adherents are fiercely protective of the prospects of its, quick to label any bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *